1 Dec 2017
We didn’t wait for the next advance against cancer. We created it.
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as “Bicycles®”, for diseases that are underserved by existing therapeutics
CEO: Kevin Lee
CIC oversight: Michael Anstey
Year of investment: 2017
- The technology is based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis.
- The company is pioneering the development of bicyclic peptides, or Bicycles® – a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date
“Despite the challenges presented by the ongoing COVID-19 pandemic, we have made significant progress towards achieving our 2020 objectives. We remain confident in our ability to achieve our near-term milestones, which should help enable our vision of pioneering the development of novel therapies for patients suffering from cancer and other serious diseases.”
Kevin Lee, CEO of Bicycle Therapeutics
Find out more about Bicycle Therapeutics